1. Home
  2. MHF vs MXCT Comparison

MHF vs MXCT Comparison

Compare MHF & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Municipal High Income Fund Inc.

MHF

Western Asset Municipal High Income Fund Inc.

SELL

Current Price

$6.24

Market Cap

136.5M

Sector

Finance

ML Signal

SELL

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

SELL

Current Price

$0.99

Market Cap

136.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MHF
MXCT
Founded
1988
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.5M
136.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MHF
MXCT
Price
$6.24
$0.99
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $4.11
AVG Volume (30 Days)
128.7K
★ 334.5K
Earning Date
01-01-0001
11-04-2026
Dividend Yield
★ 4.29%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $33,026,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18.24
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$5.84
$0.64
52 Week High
$7.33
$1.86

Technical Indicators

Market Signals
Indicator
MHF
MXCT
Relative Strength Index (RSI) 44.18 27.85
Support Level $5.84 $0.98
Resistance Level $7.05 $1.27
Average True Range (ATR) 0.20 0.05
MACD 0.03 -0.01
Stochastic Oscillator 64.41 9.73

Price Performance

Historical Comparison
MHF
MXCT

About MHF Western Asset Municipal High Income Fund Inc.

Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: